SLC5A2 and chronic kidney disease: Recent diabetes guidelines focus mainly on treating diabetes with SGLT2 inhibitors and GLP-1 RA as an add-on to metformin and lifestyle changes but based on associated comorbidities like heart failure, atherosclerosis, and chronic kidney disease, aiming to increase the percentages of patients who achieve an HbA1c < 7% for reducing chronic comorbidities [20].